Brief: Cidara Therapeutics Completes Enrollment Of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza
04/12/2024 13:55
Dec 4 (Reuters) - Cidara Therapeutics Inc CDTX.O :
* CIDARA THERAPEUTICS COMPLETES ENROLLMENT OF PHASE 2B
NAVIGATE
TRIAL EVALUATING CD388 FOR PREVENTION OF SEASONAL INFLUENZA
Source text: ID:nGNX1SJm3g
Further company coverage: CDTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cidara Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Merck Seeks Up To $8 Billion In Us Bond Sale Tied To Cidara Deal - Bloomberg News
Merck rises after Wells Fargo upgrades stock to 'overweight'
Factbox: Major deals involving U.S. drugmakers and biotechs over the past decade